{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:05:10Z","timestamp":1790373910477,"version":"4.1.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Osteoporosis guidelines do not usually provide specific recommendations regarding what medication is most appropriate for individual patients. Generic oral bisphosphonates are often considered first-line treatment for osteoporosis, but treatment duration is limited, based on potential long-term safety concerns, and there is no consensus about what to do after 5 years. There are no recommendations concerning long-term management of osteoporosis over 30 or more years of postmenopausal life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>This review attempts to specify medication choices and provide the best clinical management strategies for women at different stages of life and with different underlying disease severity. Because there is no evidence that considers the entire postmenopausal lifespan, much of the discussion here will be based on expert opinion. The review considers a role for estrogens and selective estrogen receptor modulators, oral and intravenous bisphosphonates, denosumab and the anabolic agents, teriparatide and abaloparatide.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Optimal sequential monotherapy, over an average of 30 postmenopausal years, should be able to minimize exposure to pharmacology while maximizing benefits on bone strength and minimizing imminent and long-term risk of fracture.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000509","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T18:33:31Z","timestamp":1522866811000},"page":"420-426","source":"Crossref","is-referenced-by-count":29,"title":["Long-term treatment strategies for postmenopausal osteoporosis"],"prefix":"10.1097","volume":"30","author":[{"given":"Felicia","family":"Cosman","sequence":"first","affiliation":[{"name":"Clinical Research Center, Helen Hayes Hospital, West Haverstraw, New York"},{"name":"Department of Clinical Medicine, Columbia University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/jbmr.2180","article-title":"The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system","volume":"29","author":"Solomon","year":"2014","journal-title":"J Bone Miner Res"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jbmr.2301","article-title":"The osteoporosis treatment gap","volume":"29","author":"Kanis","year":"2014","journal-title":"J Bone Miner Res"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of the North American Menopause Society","volume":"24","author":"Pinkerton","year":"2017","journal-title":"Menopause"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"5064725","DOI":"10.1155\/2017\/5064725","article-title":"The tissue-selective estrogen complex (bazedoxifene\/conjugated estrogens) for the treatment of menopause","volume":"2017","author":"Lello","year":"2017","journal-title":"Int J Endocrinol"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF Working Group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings","year":"2017","journal-title":"J Bone Miner Res"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/jbmr.2918","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteoporos Int"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Miner Res"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s00198-015-3179-x","article-title":"Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years","volume":"26","author":"Ferrari","year":"2015","journal-title":"Osteoporos Int"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","article-title":"Multiple clinical vertebral fractures following denosumab discontinuation","volume":"27","author":"Anastasilakis","year":"2016","journal-title":"Osteoporos Int"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12020-016-1030-6","article-title":"Clinical vertebral fractures following denosumab discontinuation","volume":"54","author":"Polyzos","year":"2016","journal-title":"Endocrine"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab: from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00198-017-3976-5","article-title":"Imminent fracture risk","volume":"28","author":"Roux","year":"2017","journal-title":"Osteoporos Int"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11914-010-0023-2","article-title":"Timing of subsequent fractures after an initial fracture","volume":"8","author":"van Geel","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"R25-20230829","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-018-4502-0","article-title":"Characteristics of recurrent fractures","author":"Kanis","year":"2018","journal-title":"Osteoporos Int"},{"key":"R26-20230829","article-title":"Risk of subsequent fractures after prior fracture among older women","author":"Balasubramanian","year":"2018","journal-title":"Osteoporos Int"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/jbmr.1476","article-title":"Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women","volume":"27","author":"Gehlbach","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00198-017-3948-9","article-title":"Spine fracture prevalence in a nationally representative sample of US women and men aged >\/=40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014","volume":"28","author":"Cosman","year":"2017","journal-title":"Osteoporos Int"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jocd.2016.03.003","article-title":"Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance","volume":"19","author":"Lewiecki","year":"2016","journal-title":"J Clin Densitom"},{"issue":"(Suppl 4)","key":"R30-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161435.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis: 2016","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr Pract"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2017","journal-title":"Lancet"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"R48-20230829","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","author":"Geusens","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/jbmr.1853","article-title":"Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene","volume":"28","author":"Cosman","year":"2013","journal-title":"J Bone Miner Res"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","article-title":"Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk \u2013 a perspective","volume":"27","author":"Boonen","year":"2012","journal-title":"J Bone Miner Res"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201807000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:54:15Z","timestamp":1693292055000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201807000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000509","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}